Drug Shortage - Impact on the supply of critical drugs
Abstract
In the United States (US), drug shortages have been a particularly prevalent issue, especially concerning generic drugs and biologics. These shortages affect treatments for a wide range of diseases, from mild to moderate conditions to severe life-threatening illnesses. The scarcity of oncology-related drugs is particularly concerning, as these medications play a crucial role in cancer treatment and have a direct impact on human lives. In this article, we will discuss two such drugs, Cisplatin and carboplatin, examining their causes of the current shortage and exploring potential solutions that could help alleviate these drug shortages.
Downloads
References
https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
2. Center for Drug Evaluation and Research. “Center for Drug Evaluation and Research: CDER.” U.S. Food and Drug Administration [Internet]. USFDA; 2022 Jun 21 [cited 2023 Jun 27]. Available from:
www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder
3. “FDA Drug Shortages.” FDA Drug Shortages, [Internet]. USFDA; 2023 [cited 2023 Jun 27]. Available from:
www.accessdata.fda.gov/scripts/drugshortages/default.cfm
4. Center for Drug Evaluation and Research. “Drug Shortages Infographic.” U.S. Food and Drug Administration [Internet]. USFDA; 2022 Dec. 12 [cited 2023 Jun 27]. Available from:
www.fda.gov/drugs/drug-shortages/drug-shortages-infographic
5. “Carboplatin: Use, Dosage, Side Effects, Warnings.” [Internet]. Drugs.Com; 2023 Apr. 04 [cited 2023 Jun 27]. Available from:
www.drugs.com/carboplatin.html
6. “Carboplatin.” National Cancer Institute [Internet]. NCI; 2007 Oct. 01 [cited 2023 Jun 27]. Available from:
www.cancer.gov/about-cancer/treatment/drugs/carboplatin
7. “Cisplatin.” National Cancer Institute [Internet]. NCI; 2007 Mar. 02 [cited 2023 Jun 27]. Available from:
www.cancer.gov/about-cancer/treatment/drugs/cisplatin
8. FDA Drug Shortages [Internet]. USFDA;2023 Feb. 10 [cited 2023 Jun 27]. Available from:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cisplatin%20Injection&st=c
9. FDA Drug Shortages [Internet]. USFDA; 2023 Apr. 28 [cited 2023 Jun 27]. Available from:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=c
10. Keenan, Joseph. “India’s Intas Gets More Bad News from FDA with Import Alert.” Fierce Pharma [Internet]. fiercepharma; 2023 Jun 5 [cited 2023 Jun 27]. Available from:
www.fiercepharma.com/manufacturing/indias-intas-gets-more-bad-news-fda-import-alert
11. “Import Alert 66-40.” [Internet]. USFDA; 2023 Jul. 03 [cited 2023 Jun 27]. Available from:
www.accessdata.fda.gov/cms_ia/importalert_189.html
12. “How Troubles at a Factory in India Led to a U.S. Cancer-Drug Shortage.” The Washington Post [Internet]. washingtonpost; 2023 Jun 28 [cited 2023 Jun 27]. Available from:
www.washingtonpost.com/business/2023/06/27/cancer-drug-shortage-generics/. Accessed 27 June 2023.
13. 2019 Drug Shortages Report [Internet]. USFDA; 2020 Feb. 21 [cited 2023 Jun 27]. Available from:
www.fda.gov/media/131130/download
14. Report to Congress - U.S. Food and Drug Administration [Internet]. USFDA; 2023 Jun. 07 [cited 2023 Jun 27]. Available from:
www.fda.gov/media/169302/download
15. Drug Shortages Strategic Plan 2013 [Internet]. USFDA; 2013 Oct. [cited 2023 Jul 06]. Available from:
www.fda.gov/media/86907/download
16. DHCP Letter: Temporary Importation of CISplatin Injection with non-U.S. Labeling (fda.gov) [Internet]. USFDA; 2023 May. 24 [cited 2023 Jun 27]. Available from:
www.fda.gov/media/169001/download
17. Shah S, Badjatya JK. Preliminary requirement for filing application in US. Int J Drug Reg Affairs [Internet]. 2018 Dec. 20 [cited 2023 Jun. 17];6(4):1-. Available from:
https://ijdra.com/index.php/journal/article/view/276
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM